Asbestos Health Effects

--- Page Content ---

Asbestos Health Effects
8 recognized asbestos-related diseases; IARC Group 1 carcinogen
Recognized Diseases	8 diseases
US Mesothelioma Cases/Year	~3,000
Global Asbestosis Deaths/Year	~55,000
IARC Classification	Group 1: sufficient evidence
Safe Exposure Level	None documented
Free Case Review →

Asbestos exposure causes a spectrum of diseases affecting the lungs, pleura (lung lining), and abdominal organs. The International Agency for Research on Cancer (IARC) has classified asbestos as a Group 1 carcinogen with sufficient evidence that it causes mesothelioma, lung cancer, laryngeal cancer, and ovarian cancer. Eight recognized asbestos-related diseases are documented in medical and occupational health literature, ranging from benign pleural plaques to fatal malignancies. Globally, approximately 55,000 deaths occur annually from asbestosis alone, while the United States records roughly 3,000 new mesothelioma cases per year. There is no established safe exposure threshold; even minimal occupational or environmental exposure carries documented cancer risk. The latency period from first exposure to disease manifestation ranges from 10 to 84 years depending on fiber type, exposure intensity, and individual susceptibility.

At a Glance

• 8 diseases vs. 1 carcinogen — asbestos causes more recognized diseases than any other single occupational mineral, ranging from benign plaques to fatal mesothelioma
• 500-fold potency gap between fiber types — crocidolite is 500 times more likely to cause mesothelioma than chrysotile, compared to amosite at 100 times more potent
• 30-50x lung cancer risk vs. asbestos alone — combining asbestos with smoking multiplies risk far beyond what either exposure produces independently
• 3,000 US cases per year vs. 55,000 global asbestosis deaths — mesothelioma incidence remains steady domestically while asbestosis kills 18-fold more people worldwide
• 40-45 year median latency — mesothelioma takes 3-4 times longer to appear than most occupational cancers, compared to 10-15 years for many chemical carcinogens
• Peritoneal latency nearly 3x shorter than pleural — peritoneal mesothelioma develops at a median of 8.2 years compared to 22.9 years for pleural disease
• 89% of BAPE patients have plaques — pleural plaques are found in nearly 9 out of 10 effusion cases, compared to near-zero prevalence in unexposed populations
• Immunotherapy improved survival 26% over chemotherapy — nivolumab plus ipilimumab achieved 18.1 months median survival compared to 14.1 months with pemetrexed-based treatment
• No safe threshold vs. regulated chemicals — unlike substances with established permissible limits, no minimum asbestos dose has been identified below which disease does not occur

Key Facts

Metric	Finding
Recognized Asbestos Diseases	8 diseases including mesothelioma, asbestosis, lung cancer, pleural plaques, BAPE, diffuse pleural thickening, rounded atelectasis, and laryngeal/ovarian cancer
Global Asbestosis Mortality	Approximately 55,000 deaths annually worldwide
US Mesothelioma Incidence	~3,000 new cases annually; 2,100+ deaths in 2023
IARC Classification	Group 1 carcinogen: sufficient evidence for mesothelioma, lung cancer, laryngeal cancer, ovarian cancer
Fiber Potency Ratios	Chrysotile:Amosite:Crocidolite = 1:100:500 on a fiber-for-fiber basis
Smoking Synergy	Multiplicative model: asbestos alone ~3-4x risk; smoking alone ~10x; combined = 30-50x increase
Helsinki Criteria Threshold	25 fiber-years cumulative exposure doubles lung cancer risk; 10-year minimum lag required
Median Mesothelioma Latency	40-45 years from first exposure to diagnosis (Italian registry data)
Pleural vs. Peritoneal Latency	Pleural median 22.9 years; peritoneal median 8.2 years
Mesothelin Biomarker Accuracy	61% sensitivity, 87% specificity; FDA-approved diagnostic marker
Safe Exposure Level	No minimum threshold established below which disease does not develop
CheckMate 743 Survival	Immunotherapy median OS 18.1 months vs. 14.1 months for chemotherapy; FDA approved October 2020

When Were Asbestos Health Effects First Recognized?

The medical understanding of asbestos-related disease developed over more than a century of clinical observation, often against active industry resistance. The Italian physician Bernardino Ramazzini (1633-1714) laid the groundwork for occupational medicine with his 1700 treatise De Morbis Artificum Diatriba (Diseases of Workers), which systematically catalogued diseases associated with specific trades — though he did not address asbestos specifically, his methodology inspired the field that would eventually identify asbestos hazards.

The first direct documentation of asbestos health risks came in 1898, when Lucy Deane Streatfeild, one of Britain's first female factory inspectors, published a government report describing the danger of asbestos dust to workers' lungs and the sharp, glass-like nature of the mineral particles. Her warnings were ignored. The following year, Dr. H. Montague Murray of Charing Cross Hospital performed the first autopsy linking pulmonary fibrosis to asbestos — a 33-year-old textile worker who reported that all nine of his former coworkers had died around age 30.

The landmark Merewether and Price report of 1930 examined 363 asbestos textile workers and found that 66% of those employed for 20 years or more suffered from asbestosis. This led to the Asbestos Industry Regulations 1931 — the first asbestos-specific safety regulation anywhere in the world — though these applied only to manufacturing workers and were rarely enforced. The definitive proof of asbestos causing mesothelioma came in 1960, when Wagner, Sleggs, and Marchand documented 33 cases of diffuse pleural mesothelioma among residents near South Africa's crocidolite mines — including housewives with no direct occupational exposure.

At each stage, evidence was available years or decades before regulatory action followed, a pattern that contributed to millions of preventable exposures worldwide.

What Diseases Does Asbestos Cause?

Asbestos exposure causes disease across a spectrum of severity and latency. Unlike many occupational toxins, asbestos affects the respiratory system, the pleural space surrounding the lungs, the peritoneal cavity (abdomen), and has been associated with cancers of the larynx and ovary. The diseases range from benign radiologic findings that indicate prior exposure (pleural plaques) to rapidly fatal malignancies (mesothelioma). Each disease has distinct diagnostic criteria, prognosis, and clinical features. The following table provides a comprehensive comparison of all eight recognized asbestos-related diseases:

Disease	ICD-10	Definition	Prognosis	Key Feature
Mesothelioma	C45	Malignant tumor of mesothelial cells (pleural, peritoneal, or pericardial) (details)	Median OS 18.1 months (immunotherapy); 5-year survival 12-15%	Develops 20-50+ years after exposure; no safe dose established
Asbestosis	J61	Pulmonary fibrosis from chronic asbestos inhalation; bilateral lower-lobe predominant fibrosis with asbestos bodies on histology	Progressive; ~55,000 deaths/year globally	Irreversible; requires 10+ fiber-years cumulative exposure; ~1% risk at 10 fiber-year/m3
Asbestos-Related Lung Cancer	C34	Bronchogenic carcinoma (squamous cell, adenocarcinoma, small-cell) with asbestos etiology	Same staging as non-asbestos lung cancer; poor prognosis	30-50x increased risk when combined with smoking; 10-year minimum latency
Pleural Plaques	J92.0	Non-malignant calcified/non-calcified deposits on parietal pleura; marker of prior exposure	Benign; no malignant transformation documented	Most common asbestos-related finding; appears 10-40+ years post-exposure; found in 89.1% of BAPE patients
Benign Asbestos Pleural Effusion (BAPE)	J90/J91	Non-malignant fluid accumulation in pleural space (300-2,500 mL); dyspnea, chest pain, cough	Generally resolves; may recur	Develops 15-30 years after exposure; 37.3% have concurrent rounded atelectasis; must exclude mesothelioma
Diffuse Pleural Thickening (DPT)	J92.9	Bilateral thickening of visceral pleura >=3 mm; restricts lung expansion	Restrictive lung disease; progressive	Found in 27.3% of BAPE patients; may impair gas exchange and exercise tolerance
Rounded Atelectasis	J98.1	Pulmonary collapse with characteristic "comet tail" appearance on CT; benign condition mimicking tumor	Benign; key is distinguishing from malignancy	Found in 37.3% of BAPE cases; 86% of cases associated with asbestos; diagnostic confusion with lung cancer
Laryngeal Cancer	C32	Squamous cell carcinoma of the larynx; causal relationship with asbestos established but less certain than mesothelioma	Standard cancer staging; ~50% 5-year survival	IARC: "sufficient evidence" of causation; combined relative risk ~1.4; difficult to separate from smoking confounding
Ovarian Cancer	C56	Epithelial carcinoma of the ovary; peritoneal mesothelioma may be misclassified as ovarian cancer	Standard cancer staging	IARC 2012: "sufficient evidence"; SMR 1.72 (95% CI: 1.43-2.06); diagnostic confusion with peritoneal mesothelioma

How Does Asbestos Interact with Smoking?

The interaction between asbestos exposure and cigarette smoking represents one of the most legally and epidemiologically significant relationships in occupational health. Unlike many risk factors that combine in an additive manner, asbestos and smoking demonstrate a multiplicative risk relationship for lung cancer. This means that the combined effect is substantially greater than the sum of the individual risks. Critically, smoking has been shown to have no effect on mesothelioma risk, establishing a crucial distinction in causation analysis.

The Multiplicative Model

Epidemiological studies examining workers exposed to both asbestos and tobacco smoke have consistently found that the combined risk follows a multiplicative rather than additive model:

• Asbestos alone: Increases lung cancer risk approximately 3-4 fold compared to unexposed population
• Smoking alone: Increases lung cancer risk approximately 10 fold compared to non-smokers
• Combined effect (multiplicative): 3-4x x 10x = 30-50x increased risk compared to unexposed non-smokers
• Some studies document: 50-90x increased risk for heavily exposed workers who also smoke

This multiplicative relationship has profound implications: a worker exposed to high-level asbestos who is also a smoker faces a cancer risk far exceeding what would be predicted if the risks simply added together. This evidence underlies many successful asbestos lung cancer claims, as plaintiffs can demonstrate that their disease is attributable to asbestos even in the presence of smoking history.

"The multiplicative model is not theoretical. When asbestos and smoking interact, they don't simply add 3 + 10. They multiply. A worker with 25 fiber-years of asbestos exposure and a 30-pack-year smoking history faces a risk profile fundamentally different from either exposure alone. This is the science behind attributing the cancer to asbestos, regardless of smoking status."

— Rod De Llano, Founding Partner, Danziger & De Llano

The Helsinki Criteria

The Helsinki Criteria (published in 1997 in the Scandinavian Journal of Work, Environment and Health) establish standardized diagnostic guidelines for attributing lung cancer to asbestos exposure. These criteria remain the international standard for attribution and are recognized by occupational health organizations globally:

• Cumulative exposure threshold: A minimum cumulative exposure of 25 fiber-years (f-y) is estimated to double the risk of lung cancer
• Minimum lag time: At least 10 years must elapse between first asbestos exposure and lung cancer diagnosis for attribution
• Asbestosis not required: Lung cancer can be attributed to asbestos even in the absence of radiologically evident asbestosis; the disease may develop at lower cumulative exposures
• Smoking distinction: The criteria apply to both smokers and non-smokers; smoking status does not negate asbestos causation

Smoking Does NOT Increase Mesothelioma Risk

A critical distinction in asbestos-disease causation is that smoking has no documented relationship to mesothelioma risk:

• Mesothelioma rates are equivalent in smokers and non-smokers exposed to asbestos
• Mesothelioma risk is not influenced by pack-years of cigarette smoking
• This contrasts sharply with the multiplicative interaction in asbestos-related lung cancer
• The distinction is important in causation analysis: a mesothelioma patient's smoking history is legally irrelevant to asbestos attribution

What Are the IARC Classifications?

The International Agency for Research on Cancer (IARC), a division of the World Health Organization, evaluates evidence on carcinogenic exposures and publishes authoritative monographs. The most recent comprehensive review of asbestos carcinogenicity was published in 2012, concluding that asbestos is a Group 1 carcinogen — defined as "agent is carcinogenic to humans" — with sufficient evidence in humans for multiple disease sites.

Asbestos as a Group 1 Carcinogen

IARC's Group 1 classification is the highest category, reserved for agents with the strongest evidence of human carcinogenicity. For asbestos, the 2012 Monograph determined sufficient evidence in humans that asbestos causes:

• Mesothelioma: Overwhelming epidemiological evidence from occupational cohorts, environmental clusters, and household contact studies
• Lung cancer: Consistent evidence across multiple occupational groups; dose-response relationships documented
• Laryngeal cancer: Evidence accumulating but less robust than mesothelioma or lung cancer; some inconsistency due to smoking confounding
• Ovarian cancer: Sufficient evidence based on occupational epidemiological studies and case reports; some diagnostic confusion with peritoneal mesothelioma

Evidence Grades for Individual Asbestos Types

The IARC classification applies to asbestos as a class. Regarding individual fiber types, the evidence is strongest for amphiboles (crocidolite, amosite) and also clear for chrysotile, despite ongoing industry controversy:

• Crocidolite (blue asbestos): Group 1; strongest evidence of mesothelioma causation
• Amosite (brown asbestos): Group 1; strong evidence of mesothelioma causation
• Chrysotile (white asbestos): Group 1; causation established despite being the most widely used asbestos type globally; controversy continues regarding relative potency

The IARC concludes that no asbestos type has a threshold below which disease does not occur, and that all six regulated asbestos minerals (chrysotile, amosite, crocidolite, tremolite, anthophyllite, actinolite) are carcinogenic.

How Is Asbestos-Related Disease Detected?

Early detection of asbestos-related disease during the latency period remains one of the most challenging problems in occupational medicine. Unlike acute occupational exposures that produce immediate clinical signs, asbestos diseases develop silently over decades, often detected only when symptoms of advanced disease appear. However, several detection modalities — radiographic, biomarker-based, and clinical — can identify disease at varying stages.

Biomarker Detection Windows

Three biomarkers have been studied extensively for their diagnostic potential in mesothelioma. However, none are currently recommended for population-level screening of asbestos-exposed individuals. Their clinical roles remain restricted to diagnostic confirmation in patients with suspected mesothelioma:

Biomarker	Sensitivity	Specificity	Best Use	Key Study
Mesothelin (SMRP)	61%	87%	FDA-approved diagnostic marker; most validated	Meta-analysis; AUC 0.81-0.82
Fibulin-3 (blood)	62-87%	82-89%	Diagnosis; may outperform mesothelin in some studies	Initial reports exceptional; subsequent validation lower
Fibulin-3 (pleural fluid)	84%	93%	Diagnosis and prognostic information; effusion levels predict survival	Superior prognostic value: median OS 14.1 months (below median fibulin-3) vs. 7.9 months (above median)
Osteopontin	65%	81%	Screening healthy/benign disease populations; not useful for screening other malignancies	Meta-analysis; AUC 0.83

Important caveats: Mesothelin remains the most validated diagnostic biomarker and is the FDA-approved standard. Initial fibulin-3 reports showed extraordinary accuracy (96.7% sensitivity, 95.5% specificity), but subsequent validation studies found substantially lower performance. None of these biomarkers are currently recommended for population-level screening of asbestos-exposed workers.

Pleural Plaque Development Timeline

Pleural plaques serve as a radiologic marker of prior asbestos exposure, though they are benign and do not transform to malignancy. The timeline of pleural plaque development provides important prognostic information and helps confirm asbestos exposure history:

Years After First Exposure	Prevalence of Pleural Plaques	Notes
0-10 years	0%	No cases documented in Epler et al. review of 1,135 patients
16-20 years	1.2% (bilateral)	Koskinen et al., construction/shipyard/asbestos industry workers
20 years	~10%	Epler et al.
33 years (mean)	—	Mean duration between first exposure and plaque development (Hillerdal series)
40 years	>50%	Epler et al.
40+ years (bilateral)	32.2%	Koskinen et al.
Mean time (French cohort)	47.4 years	5,392 subjects; 46.9% had pleural plaques on HRCT

Calcification of pleural plaques rarely occurs within the first 20 years of initial exposure. By 40 years, more than one-third of individuals have calcified pleural plaques. Calcification typically occurs within several years of plaques becoming radiologically evident.

"When we see bilateral pleural plaques on a chest CT in a patient with no obvious asbestos exposure history, we investigate systematically. The presence of plaques is virtually always indicative of prior asbestos exposure, even decades after the exposure occurred. Combined with occupational history, family history, or environmental residence in contaminated areas, plaques provide powerful evidence of asbestos exposure in causation analysis."

— Rod De Llano, Founding Partner, Danziger & De Llano

What Are the Current Treatment Options?

The treatment landscape for asbestos-related diseases has evolved dramatically with the approval of immunotherapy regimens. However, treatment remains palliative rather than curative, and asbestosis has no disease-modifying therapy. Clinical trials are testing emerging modalities including gene therapy, cellular therapy, and novel targeted agents.

Mesothelioma: The CheckMate 743 Breakthrough

The landmark Phase III CheckMate 743 trial (NCT02899299) published in 2020 established nivolumab plus ipilimumab immunotherapy as the first-line standard of care for unresectable mesothelioma, replacing pemetrexed-based chemotherapy after 30 years of dominance. The FDA approved this combination on October 2, 2020:

Outcome	Nivolumab + Ipilimumab	Pemetrexed + Cisplatin/Carboplatin
Median Overall Survival	18.1 months	14.1 months
2-Year Overall Survival	41%	27%
3-Year Overall Survival	23%	15%
Duration of Response	11.6 months	6.7 months
OS Improvement	26% relative improvement	—
FDA Approval Date	October 2, 2020	—

This 26% relative improvement in median overall survival, while modest, represents a meaningful advance and has become the standard of care globally. The immunotherapy regimen benefits all histological subtypes (epithelioid, sarcomatoid, biphasic) equally.

5-Year Survival Rates by Stage and Type

Despite the advances in immunotherapy, overall 5-year survival for mesothelioma remains poor, ranging from 12-15% across all stages. Survival varies significantly by stage at diagnosis:

Type/Stage	5-Year Survival Rate	Source
Pleural — Localized	23%	SEER 2015-2021
Pleural — Regional	15%	SEER
Pleural — Distant	11%	SEER
Peritoneal with CRS+HIPEC	Up to 80%	Surgical series
Epithelioid cell type	12-14%	Various
Sarcomatoid cell type	4-5%	Various
Biphasic cell type	5%	Various
Without treatment	5% (5-year); 7.9% (3-year)	Various

Peritoneal mesothelioma treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) shows dramatically superior outcomes, with some surgical series reporting 5-year survival rates up to 80%, though this reflects highly selected patient populations at specialized centers.

Emerging Clinical Trials (2025-2026)

Active research areas for mesothelioma treatment include:

• CAR-T Cell Therapy: Previously used for blood cancers; now studied for solid tumors including mesothelioma. Early 2025 trials suggest potential to slow disease progression when combined with other treatments.
• CRISPR Gene Editing: Researchers targeting and disabling genes that help mesothelioma cells survive; early-phase development.
• Viral Gene Therapy: Modified viruses delivering tumor-suppressing genes directly into tumors; combination trials with immunotherapy showing promise.
• BAP1 Mutation-Targeted Therapies: New therapies designed for patients with germline BAP1 mutations, which confer mesothelioma predisposition.
• Tumor Treating Fields (TTFields): Multi-hospital review studying TTFields for mesothelioma; emerging data from combination with standard chemotherapy.
• Combination Immunotherapy + Gene Therapy: Research showing gene therapy can enhance immunotherapy response by increasing tumor infiltration of T cells.

Asbestosis: Supportive Management Only

There is no treatment that reverses or halts asbestosis. Asbestosis remains a progressive, incurable disease. Current management is entirely supportive:

• Steroids: Provide only symptomatic relief; evidence does not consistently favor disease alleviation
• Supplemental oxygen: For hypoxemia and exercise desaturation
• Pulmonary rehabilitation: Breathing exercises and aerobic conditioning to optimize respiratory function
• Smoking cessation: Critical given the multiplicative cancer risk when asbestos and tobacco exposure coexist
• Monitoring for malignant transformation: Regular surveillance for lung cancer and mesothelioma development
• Early intervention: Outcomes are better when symptoms are identified early and supportive care is optimized
• Radiologic screening: Serial chest imaging helps identify earliest abnormal changes and may enable earlier detection of malignancy

Frequently Asked Questions

What is the most common disease caused by asbestos?

Pleural plaques are the most common asbestos-related finding, appearing in up to 89.1% of patients with benign asbestos pleural effusion. They typically develop 10-40 or more years after initial exposure and are benign markers of prior asbestos contact. Pleural plaques do not transform into cancer but indicate that other asbestos-related diseases may develop.

How long after asbestos exposure does disease develop?

The latency period varies significantly by disease type. Mesothelioma has a median latency of 40-45 years from first exposure to diagnosis, with a documented range of 10 to 84 years. Peritoneal mesothelioma shows shorter latency (median 8.2 years) compared to pleural mesothelioma (median 22.9 years). Pleural plaques typically appear 10-40 years after first exposure.

Does smoking increase the risk of mesothelioma?

No. Smoking has no documented relationship to mesothelioma risk. Mesothelioma rates are equivalent in smokers and non-smokers exposed to asbestos. However, smoking dramatically increases the risk of asbestos-related lung cancer through a multiplicative interaction, resulting in a 30-50 times greater risk compared to unexposed non-smokers.

Is there a safe level of asbestos exposure?

No minimum exposure level has been established below which asbestos-related disease does not develop. The IARC has concluded that all six regulated asbestos minerals are carcinogenic, and disease attribution is possible even at low cumulative exposures. This is why current OSHA permissible exposure limits are set as low as technically feasible rather than at a "safe" threshold.

What is the survival rate for mesothelioma?

Overall 5-year survival for mesothelioma ranges from 12-15% across all stages. The CheckMate 743 trial demonstrated that immunotherapy (nivolumab plus ipilimumab) improved median overall survival to 18.1 months compared to 14.1 months with chemotherapy. Peritoneal mesothelioma treated with CRS+HIPEC at specialized centers can achieve 5-year survival rates up to 80% in selected patients.

Which type of asbestos is most dangerous?

Crocidolite (blue asbestos) is approximately 500 times more potent than chrysotile (white asbestos) on a fiber-for-fiber basis for causing mesothelioma. Amosite (brown asbestos) is approximately 100 times more potent than chrysotile. However, the IARC classifies all asbestos types as Group 1 carcinogens, and chrysotile accounts for the majority of asbestos-related disease globally because it was the most widely used commercially.

Can asbestos cause ovarian cancer?

Yes. The IARC determined in 2012 that there is sufficient evidence that asbestos causes ovarian cancer, with a standardized mortality ratio of 1.72 (95% CI: 1.43-2.06). Some cases of peritoneal mesothelioma may be misclassified as ovarian cancer due to diagnostic similarities, making the true incidence of asbestos-related ovarian cancer difficult to determine precisely.

Are there blood tests for mesothelioma?

Mesothelin (SMRP) is the only FDA-approved blood biomarker for mesothelioma, with 61% sensitivity and 87% specificity. Fibulin-3 and osteopontin are also being studied but are not yet approved for clinical use. None of these biomarkers are currently recommended for population-level screening of asbestos-exposed workers; they are used primarily for diagnostic confirmation in patients already suspected of having mesothelioma.

Quick Statistics

• 2,100+ mesothelioma deaths recorded in the United States in 2023 alone
• 55,000 asbestosis deaths per year worldwide from chronic pulmonary fibrosis caused by inhaled asbestos fibers
• 66% of workers employed in asbestos textiles for 20+ years had asbestosis in the 1930 Merewether-Price study
• 89.1% of BAPE patients also have pleural plaques as a co-occurring finding
• 25 fiber-years is the Helsinki Criteria threshold that doubles lung cancer risk from asbestos exposure
• 18.1 months median overall survival with nivolumab plus ipilimumab immunotherapy (CheckMate 743)
• 80% 5-year survival achievable for peritoneal mesothelioma treated with CRS+HIPEC at specialized centers
• 47.4 years mean time from first exposure to pleural plaque development in a French cohort of 5,392 subjects
• 6 regulated asbestos minerals all classified as Group 1 carcinogens by the IARC
• SMR 1.72 standardized mortality ratio for asbestos-related ovarian cancer (95% CI: 1.43-2.06)

Related Pages

• Asbestos_Fiber_Types_and_Potency — Detailed analysis of chrysotile, amosite, crocidolite, and other fiber types with potency ratios
• Mesothelioma Causes and Risk Factors — Risk factors, latency mechanisms, and non-asbestos causes of mesothelioma
• Mesothelioma Latency Period — Comprehensive latency data by exposure type, age at exposure, and fiber type
• Mesothelioma Diagnosis and Staging — Clinical presentation, imaging, biomarkers, and staging systems
• Asbestos Occupational Exposure — Occupational groups at highest risk and historical exposure patterns
• Mesothelioma Treatment Options — Surgical approaches, chemotherapy, immunotherapy, and clinical trials
• Mesothelioma_Quick_Facts — Core statistics, 4 types, and survival rate reference
• Occupational_Asbestos_Exposure_Quick_Reference — 20 high-risk occupations with OSHA limits
• Mesothelioma_Settlement_Quick_Reference — Settlement and verdict ranges by case type
• Veterans_Mesothelioma_Quick_Reference — VA benefits and military branch exposure data

Get Help

If you or a loved one has been affected by asbestos exposure, resources are available:

• Danziger & De Llano — Experienced mesothelioma attorneys. Call (866) 222-9990
• Mesothelioma Lawyers Near Me — Find attorneys and take a free case evaluation quiz
• Mesothelioma.net — Patient and family resources

External Links

• Danziger & De Llano LLP — Legal representation for mesothelioma victims
• Mesothelioma Lawyer Center — Mesothelioma legal resources and information
• Mesothelioma.net — Medical and legal information on mesothelioma
• Mesothelioma Attorney — Attorney resources for asbestos claims
• IARC Asbestos Information — WHO/IARC classification and monographs
• CDC/NIOSH Asbestos Resources — Occupational health information on asbestos

This wiki page is provided for informational and educational purposes and should not be construed as legal or medical advice. Diagnosis of asbestos-related disease requires evaluation by qualified medical professionals. Attribution of disease to asbestos exposure involves complex medical and legal analysis and requires consultation with experienced occupational health physicians and attorneys. If you believe you have been exposed to asbestos or have been diagnosed with an asbestos-related disease, contact a qualified healthcare provider and consult with an asbestos litigation attorney regarding your rights.